Institutional members access full text with Ovid®

Share this article on:

Obesity Moderates the Effects of Motivational Interviewing Treatment Outcomes in Fibromyalgia

Kaleth, Anthony S. PhD*; Slaven, James E. MS; Ang, Dennis C. MD, MS

doi: 10.1097/AJP.0000000000000500
Original Articles

Objective: Obesity is a common comorbid condition among patients with fibromyalgia (FM). Our objective was to assess if obesity moderates the treatment benefits of exercise-based motivational interviewing (MI) for FM.

Materials and Methods: This is a secondary data analysis of a completed clinical trial of 198 FM patients who were randomized to receive either MI or attention control (AC). Using body mass index (BMI) to divide participants into obese (BMI≥30 kg/m2) and nonobese (BMI<30 kg m2) groups, mixed linear models were used to determine interaction between treatment arms and obesity status with regards to the primary outcome of global FM symptom severity (Fibromyalgia Impact Questionnaire, FIQ). Secondary measures included pain intensity (Brief Pain Inventory), 6-Minute Walk Test, and self-reported physical activity (Community Health Activities Model Program for Seniors).

Results: Of the 198 participants, 91 (46%) were nonobese and 107 (54%) were obese. On global FM symptom severity (FIQ), the interaction between treatment arms and obesity status was significant (P=0.02). In the nonobese group, MI was associated with a greater improvement in FIQ than AC. In the obese group, MI participants reported less improvement in FIQ compared with AC. The interaction analysis was also significant for Brief Pain Inventory pain intensity (P=0.01), but not for the walk test and self-reported physical activity.

Discussion: This is the first study to show that obesity negatively affects the treatment efficacy of MI in patients with FM. Our findings suggest that exercise-based MI may be more effective if initiated after weight loss is achieved.

*Department of Kinesiology, Indiana University-Purdue University

Department of Biostatistics, Indiana University, Indianapolis, IN

Department of Medicine, Division of Rheumatology, Wake Forest University School of Medicine, Winston-Salem, NC

Supported by National Institute of Arthritis & Musculoskeletal and Skin Diseases (1RO1AR054324-01A1), Bethesda, MD. ClinicalTrials.gov Identifier: NCT00573612. The authors declare no conflict of interest.

Reprints: Dennis Ang, MD, MS, Section of Rheumatology and Immunology, Wake Forest University Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157 (e-mail: dang@wakehealth.edu).

Received October 6, 2016

Received in revised form February 17, 2017

Accepted February 28, 2017

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.